Windlas Biotech Board approved buyback of 4.70 lakh shares at ₹1,000 per share via tender offer route.
Buyback represents 2.23% of paid-up capital with ₹47 crore maximum outlay, excluding promoters.
Record date fixed as April 24, 2026; Fintellectual appointed as merchant banker for the process.
Pre-buyback shareholding shows promoters hold 61.90% with 19.48% held by small retail investors.